The aims of this study were to (a) characterize the expression of PRDM1 across different cancer types; (b) assess the prognostic values of PRDM1 across different tumors; (c) evaluate the associations between PRDM1 and tumor immunity features including intratumoral immune infiltrates, checkpoint markers, tumor mutation burden (TMB), microsatellite instability (MSI), which have been identified as potential biomarkers for predicting response to immune checkpoint inhibitor treatment, and (d) evaluate its correlations with drugs response. This evidence concerns the gene PRDM1 and neoplasm.